OCG Mission
The mission of the NCI’s Office of Cancer Genomics (OCG) is to advance the molecular understanding of cancers with the goal to improve patient outcomes. OCG supports structural, functional, and translational genomic programs, as well as the development of next generation cancer models, to accelerate the translation of findings into the clinic and contribute to precision oncology.
CURRENT PROGRAMS
 |
The Cancer Genome Characterization Initiative (CGCI) uses molecular characterization to uncover distinct features of rare cancers. Current projects perform comprehensive molecular cataloging of HIV+ and other rare adult and pediatric cancers. The research community can use CGCI data to gain insights into the underlying mechanisms of these cancers and identify potential therapeutic targets. |
 |
The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. |
 |
The Human Cancer Models Initiative (HCMI) is an international consortium that is generating novel, next-generation, tumor-derived culture models annotated with genomic, clinical, and biospecimen data. HCMI-developed models and case-associated data are available as a community resource. NCI is contributing to the initiative by supporting four Cancer Model Development Centers (CMDCs). |
 |
Next-Generation Technologies (NGT) Program supports the development of technology tools that will facilitate, accelerate, and/or enhance research using advanced human-derived next-generation cancer models such as organoids, conditionally reprogrammed cells, and others. The technology tools will focus on utilizing next-generation cancer models from the Human Cancer Models Initiative. |
 |
The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. The goal of the program is to use data to guide the development of effective, less toxic therapies. TARGET is organized into a collaborative network of disease-specific project teams. |
DATA ACCESS
The OCG furthers its mission to advance and accelerate genomics science by disseminating the data and resources generated by OCG supported programs to the research community.
